Anne Sophie Voisin-chiret

List of Publications by Year
in descending order

35 papers	788 citations	623188 14 h-index	525886 27 g-index
35 all docs	35 docs citations	35 times ranked	1017 citing authors

#	Article	IF	Citations
1	Tau protein aggregation: Key features to improve drug discovery screening. Drug Discovery Today, 2022, 27, 1284-1297.	3.2	12
2	Strategies to Reduce the Onâ€Target Platelet Toxicity of Bclâ€x_L Inhibitors: PROTACs, SNIPERs and Prodrugâ€Based Approaches. ChemBioChem, 2022, 23, .	1.3	27
3	Azobenzene Photoswitches in Proteolysis Targeting Chimeras: Photochemical Control Strategies and Therapeutic Benefits. ChemistrySelect, 2022, 7, .	0.7	11
4	Structural revision of the Mcl-1 inhibitor MIM1. Synthesis and biological studies on ovarian cancer cells with evaluation of designed analogues. Organic and Biomolecular Chemistry, 2021, 19, 8968-8987.	1.5	1
5	Nutrient Requirements during Pregnancy and Lactation. Nutrients, 2021, 13, 692.	1.7	45
6	Cryptic Pockets Repository through Pocket Dynamics Tracking and Metadynamics on Essential Dynamics Space: Applications to Mcl-1. Journal of Chemical Information and Modeling, 2021, 61, 5581-5588.	2.5	3
7	Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1. Drug Design, Development and Therapy, 2021, Volume 15, 5035-5059.	2.0	2
8	Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy. Cell Death and Differentiation, 2020, 27, 117-129.	5.0	31
9	Hot-Spots of Mcl-1 Protein. Journal of Medicinal Chemistry, 2020, 63, 928-943.	2.9	57
10	Binding mode of Pyridoclax to myeloid cell leukemia-1 (Mcl-1) revealed by nuclear magnetic resonance spectroscopy, docking and molecular dynamics approaches. Journal of Biomolecular Structure and Dynamics, 2020, 38, 4162-4178.	2.0	4
11	Synthesis of Pyridoclax Analogues: Insight into Their Druggability by Investigating Their Physicochemical Properties and Interactions with Membranes. ChemMedChem, 2020, 15, 136-154.	1.6	4
12	Noncellular screening for the discovery of proteinâ€“protein interaction modulators. Drug Discovery Today, 2020, 25, 1592-1603.	3.2	6
13	Pyridoclax-loaded nanoemulsion for enhanced anticancer effect on ovarian cancer. International Journal of Pharmaceutics, 2020, 587, 119655.	2.6	11
14	Br vs. TsO Chemoselective Suzukiâ€“Miyaura Crossâ€Coupling Reaction on Nicotinaldehyde Moiety for the Preparation of 2,3,5â€Trisubstituted Pyridines. European Journal of Organic Chemistry, 2020, 2020, 3640-3649.	1.2	7
15	Insights into Mcl-1 Conformational States and Allosteric Inhibition Mechanism from Molecular Dynamics Simulations, Enhanced Sampling, and Pocket Crosstalk Analysis. Journal of Chemical Information and Modeling, 2020, 60, 3172-3187.	2.5	9
16	Catalytic Friedelâ€Crafts Reactions on Saturated Heterocycles and Small Rings for sp³â€sp² Coupling of Medicinally Relevant Fragments. European Journal of Organic Chemistry, 2019, 2019, 5385-5395.	1.2	13
17	Microplate assay for lipophilicity determination using intrinsic fluorescence of drugs: Application to a promising anticancer lead, pyridoclax. European Journal of Pharmaceutical Sciences, 2019, 131, 75-83.	1.9	6
18	Synthesis of 3,3-Diarylazetidines by Calcium(II)-Catalyzed Friedelâ€“Crafts Reaction of Azetidinols with Unexpected Cbz Enhanced Reactivity. Organic Letters, 2019, 21, 300-304.	2.4	26

#	Article	IF	Citations
19	Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode. European Journal of Medicinal Chemistry, 2018, 159, 357-380.	2.6	12
20	Toward Understanding Mcl-1 Promiscuous and Specific Binding Mode. Journal of Chemical Information and Modeling, 2017, 57, 2885-2895.	2.5	13
21	Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents. European Journal of Medicinal Chemistry, 2017, 139, 153-167.	2.6	167
22	First Evidence That Oligopyridines, Î±-Helix Foldamers, Inhibit Mcl-1 and Sensitize Ovarian Carcinoma Cells to Bcl-x_L-Targeting Strategies. Journal of Medicinal Chemistry, 2015, 58, 1644-1668.	2.9	40
23	Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: Study of 6-substituted pyridine-3-boronic acid derivatives. European Journal of Medicinal Chemistry, 2015, 95, 185-198.	2.6	51
24	First Identification of Boronic Species as Novel Potential Inhibitors of the Staphylococcus aureus NorA Efflux Pump. Journal of Medicinal Chemistry, 2014, 57, 2536-2548.	2.9	63
25	Conformation Control of Abiotic Î±-Helical Foldamers. Journal of Chemical Information and Modeling, 2013, 53, 2671-2680.	2.5	7
26	Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues. Current Medicinal Chemistry, 2013, 20, 2964-2978.	1.2	9
27	Using halo (het) arylboronic species to achieve synthesis of foldamers as proteinâ€“protein interaction disruptors. Pure and Applied Chemistry, 2012, 84, 2467-2478.	0.9	6
28	Structural Characterizations of Oligopyridyl Foldamers, Î±-Helix Mimetics. Journal of Chemical Information and Modeling, 2012, 52, 429-439.	2.5	15
29	Synthesis of new linear poly(phenylpyridyl) chains. Tetrahedron, 2012, 68, 1910-1917.	1.0	14
30	Aromatic garlands, as new foldamers, to mimic protein secondary structure. Tetrahedron, 2012, 68, 4381-4389.	1.0	7
31	Design and synthesis of thienylpyridyl garlands as non-peptidic alpha helix mimetics and potential proteinâ€“protein interactions disruptors. Tetrahedron, 2011, 67, 6145-6154.	1.0	24
32	Synthesis of new phenylpyridyl scaffolds using the Garlanding approach. Tetrahedron, 2010, 66, 8000-8005.	1.0	24
33	Synthesis of dihalo bi- and terpyridines by regioselective Suzukiâ€“Miyaura cross-coupling reactions. Tetrahedron, 2009, 65, 5413-5417.	1.0	26
34	A general synthesis of halo-oligopyridines. The Garlanding concept. Tetrahedron, 2009, 65, 607-612.	1.0	35
35	Synthesis and biological evaluation of FJ-809, a compound originally described as MIM1 and inhibitor of the anti-apoptotic protein Mcl-1.. New Journal of Chemistry, 0, , .	1.4	0